SinoMab BioScience (4VF) Stock Overview
A biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases primarily monoclonal antibody (mAb)-based biologics in Mainland China and Hong Kong. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
4VF Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
SinoMab BioScience Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.13 |
| 52 Week High | HK$0.22 |
| 52 Week Low | HK$0.10 |
| Beta | 0.65 |
| 1 Month Change | -6.67% |
| 3 Month Change | -27.59% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -37.19% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4VF | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -1.2% | -2.5% |
| 1Y | n/a | 14.7% | -0.6% |
Return vs Industry: Insufficient data to determine how 4VF performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how 4VF performed against the German Market.
Price Volatility
| 4VF volatility | |
|---|---|
| 4VF Average Weekly Movement | 12.5% |
| Biotechs Industry Average Movement | 8.2% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in DE Market | 12.7% |
| 10% least volatile stocks in DE Market | 2.8% |
Stable Share Price: 4VF's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine 4VF's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 95 | Shawn Leung | www.sinomab.com |
SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases primarily monoclonal antibody (mAb)-based biologics in Mainland China and Hong Kong. Its product pipeline comprises SM03 (Suciraslimab), a first-in-class anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA); is in phase II clinical trial to treat non-Hodgkin’s lymphoma and systemic lupus erythematosus; and is in phase I clinical trial to treat alzheimer’s disease and sjogren’s syndrome. It also develops SM17, a humanized anti-IL-25 receptor, which is in phase I clinical trial to treat asthma and atopic dermatitis, as well as to treat idiopathic pulmonary fibrosis; and SN1011, a Bruton’s tyrosine kinase inhibitor, which is in Phase II clinical trial for the treatment of pemphigus, neuromyelitis optical spectrum disorder, and multiple sclerosis, as well as to treat systemic lupus erythematosus.
SinoMab BioScience Limited Fundamentals Summary
| 4VF fundamental statistics | |
|---|---|
| Market cap | €184.39m |
| Earnings (TTM) | -€13.57m |
| Revenue (TTM) | n/a |
Is 4VF overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4VF income statement (TTM) | |
|---|---|
| Revenue | CN¥0 |
| Cost of Revenue | CN¥0 |
| Gross Profit | CN¥0 |
| Other Expenses | CN¥104.99m |
| Earnings | -CN¥104.98m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.076 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 64.3% |
How did 4VF perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/13 04:10 |
| End of Day Share Price | 2026/07/10 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
SinoMab BioScience Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yue-Kwong Lui | Jefferies LLC |